Twenty-nine patients with advanced refractory multiple myeloma were treated with intermittent high-dose dexamethasone in combination with four-day infusions of vincristine and doxorubicin. Rapid and marked tumor-mass reduction (greater than 75 per cent) was noted in 14 of 20 patients whose disease was resistant to alkylating agents and in 3 of 9 patients with additional resistance to doxorubicin--a result far superior to those in previous trials with similar patients. In responsive patients, remissions were of excellent quality, and survival was significantly longer than in unresponsive patients.
This article has been cited by other articles:
Kumar, S. K., Mikhael, J. R., Buadi, F. K., Dingli, D., Dispenzieri, A., Fonseca, R., Gertz, M. A., Greipp, P. R., Hayman, S. R., Kyle, R. A., Lacy, M. Q., Lust, J. A., Reeder, C. B., Roy, V., Russell, S. J., Short, K. E. D., Stewart, A. K., Witzig, T. E., Zeldenrust, S. R., Dalton, R. J., Rajkumar, S. V., Bergsagel, P. L.
(2009). Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines. Mayo Clin Proc.
84: 1095-1110
[Abstract][Full Text]
Kettle, J. K, Finkbiner, K. L, Klenke, S. E, Baker, R. D, Henry, D. W, Williams, C. B
(2009). Initial therapy in multiple myeloma: investigating the new treatment paradigm. J Oncol Pharm Pract
15: 131-141
[Abstract]
Katzel, J. A., Hari, P., Vesole, D. H.
(2007). Multiple Myeloma: Charging Toward a Bright Future. CA Cancer J Clin
57: 301-318
[Abstract][Full Text]
Wang, M., Zhang, L., Han, X., Yang, J., Qian, J., Hong, S., Samaniego, F., Romaguera, J., Yi, Q.
(2007). Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood
109: 5455-5462
[Abstract][Full Text]
Kristinsson, S. Y., Landgren, O., Dickman, P. W., Derolf, A. R., Bjorkholm, M.
(2007). Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003. JCO
25: 1993-1999
[Abstract][Full Text]
Dispenzieri, A., Rajkumar, S. V., Gertz, M. A., Lacy, M. Q., Kyle, R. A., Greipp, P. R., Witzig, T. E., Lust, J. A., Russell, S. J., Hayman, S. R., Kumar, S., Zeldenrust, S. R., Fonseca, R., Bergsagel, P. L., Reeder, C. B., Stewart, A. K., Roy, V., Dalton, R. J.
(2007). Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement. Mayo Clin Proc.
82: 323-341
[Abstract][Full Text]
Palmieri, C., Treibel, T., Large, O., Bower, M.
(2006). AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy. QJM
99: 811-826
[Abstract][Full Text]
Lacy, M. Q.
(2006). Multiple Myeloma: New Options, New Challenges. Mayo Clin Proc.
81: 877-879
[Full Text]
Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., Lee, C., Talamo, G., Thertulien, R., Kiwan, E., Krishna, S., Fox, M., Crowley, J.
(2006). Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma. NEJM
354: 1021-1030
[Abstract][Full Text]
Barlogie, B., Kyle, R. A., Anderson, K. C., Greipp, P. R., Lazarus, H. M., Hurd, D. D., McCoy, J., Dakhil, S. R., Lanier, K. S., Chapman, R. A., Cromer, J. N., Salmon, S. E., Durie, B., Crowley, J. C.
(2006). Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321. JCO
24: 929-936
[Abstract][Full Text]
Saunders, G.
(2005). Overview of drug therapy for multiple myeloma. J Oncol Pharm Pract
11: 83-100
[Abstract]
Rajkumar, S. V.
(2005). Multiple myeloma: the death of VAD as initial therapy. Blood
106: 2-3
[Full Text]
Sano, H. S, Waddell, J A., A Solimando, D. Jr, Doulaveris, P., Myhand, R.
(2005). Study of the effect of standardized chemotherapy order forms on prescribing errors and anti-emetic cost. J Oncol Pharm Pract
11: 21-30
[Abstract]
Richardson, P. G., Kassarjian, A., Jing, W.
(2004). Case 38-2004 - A 40-Year-Old Man with a Large Tumor of the Skull. NEJM
351: 2637-2645
[Full Text]
Kiewe, P., Jovanovic, S., Thiel, E., Korfel, A.
(2004). Reversible Ageusia after Chemotherapy with Pegylated Liposomal Doxorubicin. The Annals of Pharmacotherapy
38: 1212-1214
[Abstract][Full Text]
Sparano, J. A., Lee, S., Chen, M. G., Nazeer, T., Einzig, A., Ambinder, R. F., Henry, D. H., Manalo, J., Li, T., Von Roenn, J. H.
(2004). Phase II Trial of Infusional Cyclophosphamide, Doxorubicin, and Etoposide in Patients With HIV-Associated Non-Hodgkin's Lymphoma: An Eastern Cooperative Oncology Group Trial (E1494). JCO
22: 1491-1500
[Abstract][Full Text]
Barlogie, B., Shaughnessy, J., Tricot, G., Jacobson, J., Zangari, M., Anaissie, E., Walker, R., Crowley, J.
(2004). Treatment of multiple myeloma. Blood
103: 20-32
[Abstract][Full Text]
Dimopoulos, M. A., Anagnostopoulos, A., Weber, D.
(2003). Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives. JCO
21: 4444-4454
[Abstract][Full Text]
Rowinsky, E. K.
(2003). Crossing the Cancer Cell Membrane to Improve Clinical Outcomes. The Oncologist
8: 1-4
[Full Text]
Hussein, M. A.
(2003). Modifications to Therapy for Multiple Myeloma: Pegylated Liposomal Doxorubicin in Combination With Vincristine, Reduced-Dose Dexamethasone, and Thalidomide. The Oncologist
8: 39-45
[Abstract][Full Text]
Lee, C.-K., Barlogie, B., Munshi, N., Zangari, M., Fassas, A., Jacobson, J., van Rhee, F., Cottler-Fox, M., Muwalla, F., Tricot, G.
(2003). DTPACE: An Effective, Novel Combination Chemotherapy With Thalidomide for Previously Treated Patients With Myeloma. JCO
21: 2732-2739
[Abstract][Full Text]
Dimopoulos, M. A., Pouli, A., Zervas, K., Grigoraki, V., Symeonidis, A., Repoussis, P., Mitsouli, C., Papanastasiou, C., Margaritis, D., Tokmaktsis, A., Katodritou, I., Kokkini, G., Terpos, E., Vyniou, N., Tzilianos, M., Chatzivassili, A., Kyrtsonis, M. C., Panayiotidis, P., Maniatis, A.
(2003). Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol
14: 1039-1044
[Abstract][Full Text]
Dumontet, C., Jaubert, J., Sebban, C., Bouafia, F., Ardiet, C., Tranchand, B., Berger, E., Lucas, C., Guyotat, D., Coiffier, B.
(2003). Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients. Ann Oncol
14: 615-622
[Abstract][Full Text]
Sparano, J. A., Weller, E., Nazeer, T., Habermann, T., Traynor, A. E., Manalo, J., Cassileth, P.
(2002). Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493). Blood
100: 1634-1640
[Abstract][Full Text]
Spanswick, V. J., Craddock, C., Sekhar, M., Mahendra, P., Shankaranarayana, P., Hughes, R. G., Hochhauser, D., Hartley, J. A.
(2002). Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood
100: 224-229
[Abstract][Full Text]
Cany, L., Fitoussi, O., Boiron, J.M., Marit, G.
(2002). Tumor Lysis Syndrome at the Beginning of Thalidomide Therapy for Multiple Myeloma. JCO
20: 2212-2212
[Full Text]
Moehler, T. M., Neben, K., Benner, A., Egerer, G., Krasniqi, F., Ho, A. D., Goldschmidt, H.
(2001). Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood
98: 3846-3848
[Abstract][Full Text]
Zaidi, A. A., Vesole, D. H.
(2001). Multiple Myeloma: An Old Disease with New Hope for the Future. CA Cancer J Clin
51: 273-285
[Abstract][Full Text]
Dalton, W. S., Bergsagel, P. L., Kuehl, W. M., Anderson, K. C., Harousseau, J. L.
(2001). Multiple Myeloma. ASH Education Book
2001: 157-177
[Abstract][Full Text]
Ozer, H., Armitage, J. O., Bennett, C. L., Crawford, J., Demetri, G. D., Pizzo, P. A., Schiffer, C. A., Smith, T. J., Somlo, G., Wade, J. C., Wade, J. L. III, Winn, R. J., Wozniak, A. J., Somerfield, M. R., for the American Society of Clinical Oncology Gro,
(2000). 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines. JCO
18: 3558-3585
[Full Text]
Lokhorst, H. M., Schattenberg, A., Cornelissen, J. J., van Oers, M. H. J., Fibbe, W., Russell, I., Donk, N. W. C. J. v. d., Verdonck, L. F.
(2000). Donor Lymphocyte Infusions for Relapsed Multiple Myeloma After Allogeneic Stem-Cell Transplantation: Predictive Factors for Response and Long-Term Outcome. JCO
18: 3031-3037
[Abstract][Full Text]
Anderson, K. C., Kyle, R. A., Dalton, W. S., Landowski, T., Shain, K., Jove, R., Hazlehurst, L., Berenson, J.
(2000). Multiple Myeloma: New Insights and Therapeutic Approaches. ASH Education Book
2000: 147-165
[Abstract][Full Text]
Vesole, D. H., Crowley, J. J., Catchatourian, R., Stiff, P. J., Johnson, D. B., Cromer, J., Salmon, S. E., Barlogie, B.
(1999). High-Dose Melphalan With Autotransplantation for Refractory Multiple Myeloma: Results of a Southwest Oncology Group Phase II Trial. JCO
17: 2173-2173
[Abstract][Full Text]
Kishi, S., Goto, N., Nakamura, T., Ueda, T.
(1999). Evaluation of Cell-killing Effects of 1-{beta}-D-Arabinofuranosylcytosine and Daunorubicin by a New Computer-controlled in Vitro Pharmacokinetic Simulation System. Cancer Res.
59: 2629-2634
[Abstract][Full Text]
Barlogie, B., Jagannath, S., Desikan, K.R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., Mehta, J., Anaissie, E., Dhodapkar, D., Naucke, S., Cromer, J., Sawyer, J., Epstein, J., Spoon, D., Ayers, D., Cheson, B., Crowley, J.
(1999). Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma. Blood
93: 55-65
[Abstract][Full Text]
Priston, M. J, Sewell, G. J
(1998). Stability of three cytotoxic drug infusions in the Graseby 9000 ambulatory infusion pump. J Oncol Pharm Pract
4: 143-149
[Abstract]
Lokhorst, H.M., Schattenberg, A., Cornelissen, J.J., Thomas, L.L.M., Verdonck, L.F.
(1997). Donor Leukocyte Infusions Are Effective in Relapsed Multiple Myeloma After Allogeneic Bone Marrow Transplantation. Blood
90: 4206-4211
[Abstract][Full Text]
Barlogie, B., Jagannath, S., Vesole, D. H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J., Tricot, G.
(1997). Superiority of Tandem Autologous Transplantation Over Standard Therapy for Previously Untreated Multiple Myeloma. Blood
89: 789-793
[Abstract][Full Text]
MacLennan, I C M, Drayson, M, Dunn, J
(1994). Current Issues in Cancer: Multiple myeloma. BMJ
308: 1033-1036
[Full Text]
Alexanian, R., Dimopoulos, M.
(1994). The Treatment of Multiple Myeloma. NEJM
330: 484-489
[Full Text]
Dunbar, C. E., Nienhuis, A. W.
(1993). Multiple Myeloma: New Approaches to Therapy. JAMA
269: 2412-2416
[Abstract]
Barlogie, B., Alexanian, R., Jagannath, S.
(1992). Plasma Cell Dyscrasias. JAMA
268: 2946-2951
[Abstract]
Graves, T., Pruemer, J.
(1991). New Methods of Chemotherapy Administration-Selected Routes. Journal of Pharmacy Practice
4: 49-63
Barlogie, B., Smallwood, L., Smith, T., Alexanian, R.
(1989). High Serum Levels of Lactic Dehydrogenase Identify a High-Grade Lymphoma-like Myeloma. ANN INTERN MED
110: 521-525
[Abstract]
ALEXANIAN, R., BARLOGIE, B., DIXON, D.
(1986). High-Dose Glucocorticoid Treatment of Resistant Myeloma. ANN INTERN MED
105: 8-11
[Abstract]
Alexanian, R.
(1985). Ten-Year Survival in Multiple Myeloma. Arch Intern Med
145: 2073-2074
[Abstract]
Previous
